{
    "id": 30248,
    "fullName": "NFE2L2 F37V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NFE2L2 F37V lies within the NEH2 domain of the Nfe2l2 protein (PMID: 23936606). F37V has not been characterized in the scientific literature and therefore, its effect on Nfe2l2 protein function is unknown (PubMed, Jun 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 3570,
                    "pubMedId": 23936606,
                    "title": "Genomic structure and variation of nuclear factor (erythroid-derived 2)-like 2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23936606"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4780,
        "geneSymbol": "NFE2L2",
        "terms": [
            "NFE2L2",
            "HEBP1",
            "IMDDHH",
            "Nrf-2",
            "NRF2"
        ]
    },
    "variant": "F37V",
    "createDate": "06/03/2019",
    "updateDate": "06/03/2019",
    "referenceTranscriptCoordinates": {
        "id": 179851,
        "transcript": "NM_006164",
        "gDna": "chr2:g.177234208A>C",
        "cDna": "c.109T>G",
        "protein": "p.F37V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17253,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Sapanisertib (MLN0128) treatment of a squamous cell lung cancer patient, harboring NFE2L2 F37V, resulted in a duration of response of 5.5 months and was ongoing (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 9098-9098).",
            "molecularProfile": {
                "id": 32398,
                "profileName": "NFE2L2 F37V"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15272,
                    "pubMedId": null,
                    "title": "Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32398,
            "profileName": "NFE2L2 F37V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 179850,
            "transcript": "NM_001313902",
            "gDna": "chr2:g.177234208A>C",
            "cDna": "c.109T>G",
            "protein": "p.F37V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 179851,
            "transcript": "NM_006164",
            "gDna": "chr2:g.177234208A>C",
            "cDna": "c.109T>G",
            "protein": "p.F37V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}